BioSpecifics Technologies Corp. is a profitable, biopharmaceutical company that has been involved in the development of injectable collagenase (CCH) for multiple indications. CCH is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Canada, Europe and Australia.

In addition to Dupuytren's contracture and Peyronie's disease, Endo is managing the research and development of CCH for their six licensed clinical-stage indications, which include adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis and human and canine lipomas. BioSpecifics is currently managing the development of CCH for uterine fibroids in an ongoing Phase 1 clinical trial with top-line data expected in the fourth quarter of 2018. Promising interim data was reported at the 65th Annual Scientific Meeting of the Society for Reproductive Investigation as well preclinical data from a collaborative study with Duke Medicine. BioSpecifics also initiates the development of CCH in new potential indications. Endo has the right to opt in to new indications.